Vericiguat: A Randomized, Phase Ib, Placebo-Controlled, Double-Blind, QTc Interval Study in Patients with Chronic Coronary Syndromes

BACKGROUND: Vericiguat is indicated for the treatment of symptomatic chronic heart failure in adult patients with reduced ejection fraction who are stabilized after a recent decompensation event. OBJECTIVE: To investigate the effects of vericiguat on QT interval in patients with chronic coronary syn...

Descripción completa

Detalles Bibliográficos
Autores principales: Böttcher, Michael, Düngen, Hans-Dirk, Corcea, Vasile, Donath, Frank, Fuhr, Rainard, Gal, Pim, Mikus, Gerd, Trenk, Dietmar, Coenen, Martin, Pires, Philippe Vieira, Maschke, Claudia, Aliprantis, Antonios Othon, Besche, Nina, Becker, Corina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10006255/
https://www.ncbi.nlm.nih.gov/pubmed/36633816
http://dx.doi.org/10.1007/s40256-022-00557-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10006255/
https://www.ncbi.nlm.nih.gov/pubmed/36633816
http://dx.doi.org/10.1007/s40256-022-00557-2

Ejemplares similares